SCHEMBL20091027

SCHEMBL20091027

CCCCCCOCc1c(Cl)cccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ADRB2 P07550 2/20 0.41
ADRB1 P08588 2/20 0.41
MLNR O43193 1/20 0.41
NR1I2 O75469 1/20 0.41
ABCB11 O95342 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
DRD1 P21728 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2A P28223 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
PTGS2 P35354 1/20 0.41
MC3R P41968 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PDE4D Q08499 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17031686 0.97 KDM4E (0.46) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL20091058 0.89 KMT2A (0.57) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL15614733 0.87 ADRB2 (0.49) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL18596661 0.81 IDO1 (0.47) KDM4ENR5A1TSHRLMNAALDH1A1
SCHEMBL926932 0.79 ADRB2 (0.45) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL15614735 0.79 ADRB2 (0.50) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL924842 0.79 ADRB2 (0.45) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL15614684 0.79 ADRB2 (0.45) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL29018766 0.79 ADRB2 (0.50) KDM4EPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL13595513 0.79 ADRB2 (0.45) KDM4EPOLBMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-09-24 US disclosed
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE LYCERA CORPORATION 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE RORB, RORA, RORC KDM4E 2051/4885POLB 3181/4885MEN1 3786/4885
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORB, RORA, RORC KDM4E 2334/4885POLB 3055/4885MEN1 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.